Fraxinellone (oral gavage; 30 and 100 mg/kg; every three days; 30 days) significantly suppresses tumor growth, reduces HIF-1α, pTyr705 STAT3, PD-L1 and VEGF staining compared with the control group in female athymic BALB/c nude mice[1]. Animal Model: BALB/c nude mice[1] Dosage: 30 and 100 mg/kg Administration: Oral gavage; 30 and 100 mg/kg; every three days; 30 days Result: Significantly suppressed tumor growth.
In Vitro
Fraxinellone (0-100 μM；12 hours) decreases the percent of PD-L1 positive cells from 20.4% to 11.4% in A549 cells[1]. Cell Viability Assay[1] Cell Line: A549 cells Concentration: 0 μM, 10 μM, 30 μM, 100 μM Incubation Time: 12 hours Result: Inhibited the percent of PD-L1 positive cells.
Kinase Assay
Cell Assay
Animal Administration
References
[1]. Xing Y, et al. Fraxinellone has anticancer activity in vivo by inhibiting programmed cell death-ligand 1 expression by reducing hypoxia-inducible factor-1α and STAT3. Pharmacol Res. 2018 Sep;135:166-180.
Return Policy
If you are in any way unsatisfied with your purchase, you may return any item(s) within 365 days of its original purchase date.
Please provide your Order Number in the email. We strive to reply to all email inquiries within one business day.
